1,066 results on '"Geisbert, Thomas W."'
Search Results
2. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus
3. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection
4. Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects
5. Nonhuman Primate Models for Nipah and Hendra Virus Countermeasure Evaluation
6. Overview of Experimental Vaccines and Antiviral Therapeutics for Henipavirus Infection
7. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates
8. A Glass-Half-Full Perspective on Negative Data in Ebolavirus Vaccine Studies
9. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus
10. Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
11. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease
12. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates
13. Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein
14. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
15. Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever
16. Establishment of an African green monkey model for COVID-19 and protection against re-infection
17. Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
18. Combination therapy protects macaques against advanced Marburg virus disease
19. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
20. High-Avidity Anti-Filovirus IgG Elicited Using Protein Subunit Vaccines Does Not Correlate with Protection
21. Revisiting the minimum incubation period of Zaire ebolavirus
22. Animal Models for Henipavirus Research
23. Modelling Marburg Virus Disease in Syrian Golden Hamsters: Contrasted Virulence between Angola and Ci67 strains
24. Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting
25. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus
26. Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret ( Mustela putorius furo )
27. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates
28. Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans
29. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms
30. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
31. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
32. Antibody therapy for Lassa fever
33. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death
34. Marburg and Ravn Viruses (Filoviridae)
35. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections
36. Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection.
37. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques.
38. The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in Ferrets.
39. Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody.
40. Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona.
41. A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus.
42. Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates.
43. A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.
44. Limited benefit of post-exposure prophylaxis with VSV-EBOV in Ebola virus-infected rhesus macaques
45. A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus
46. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
47. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
48. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase
49. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop
50. Antibodies periodically wax and wane in survivors of Ebola
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.